ALK and non-small cell lung carcinoma: Driver mutations—including epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements—have clinical significance in the treatment of non-small-cell lung cancer (NSCLC).